153 related articles for article (PubMed ID: 23916860)
1. Ring chromosome 20: a pediatric potassium channelopathy responsive to treatment with ezogabine.
Walleigh DJ; Legido A; Valencia I
Pediatr Neurol; 2013 Nov; 49(5):368-9. PubMed ID: 23916860
[TBL] [Abstract][Full Text] [Related]
2. The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy.
Gunthorpe MJ; Large CH; Sankar R
Epilepsia; 2012 Mar; 53(3):412-24. PubMed ID: 22220513
[TBL] [Abstract][Full Text] [Related]
3. Ezogabine treatment of childhood absence epilepsy.
Vossler DG; Yilmaz U
Epileptic Disord; 2014 Mar; 16(1):121-4. PubMed ID: 24659629
[TBL] [Abstract][Full Text] [Related]
4. [Ring chromosome 20: an epileptic channel disorder?].
Serrano-Castro PJ; Aguilar-Castillo MJ; Olivares-Romero J; Jiménez-Machado R; Molina-Aparicio MJ
Rev Neurol; 2001 Feb 1-15; 32(3):237-41. PubMed ID: 11310277
[TBL] [Abstract][Full Text] [Related]
5. Ezogabine (retigabine) and its role in the treatment of partial-onset seizures: a review.
Splinter MY
Clin Ther; 2012 Sep; 34(9):1845-56.e1. PubMed ID: 22917854
[TBL] [Abstract][Full Text] [Related]
6. Retigabine/Ezogabine, a KCNQ/K(V)7 channel opener: pharmacological and clinical data.
Orhan G; Wuttke TV; Nies AT; Schwab M; Lerche H
Expert Opin Pharmacother; 2012 Aug; 13(12):1807-16. PubMed ID: 22783830
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability exposure-response relationship of retigabine (ezogabine) immediate-release tablets in patients with partial-onset seizures.
Tompson DJ; Crean CS; Reeve R; Berry NS
Clin Ther; 2013 Aug; 35(8):1174-1185.e4. PubMed ID: 23916044
[TBL] [Abstract][Full Text] [Related]
8. Safety profile of two novel antiepileptic agents approved for the treatment of refractory partial seizures: ezogabine (retigabine) and perampanel.
Faulkner MA; Burke RA
Expert Opin Drug Saf; 2013 Nov; 12(6):847-55. PubMed ID: 23883095
[TBL] [Abstract][Full Text] [Related]
9. The preclinical discovery and development of ezogabine for the treatment of epilepsy.
Jankovic S; Ilickovic I
Expert Opin Drug Discov; 2013 Nov; 8(11):1429-37. PubMed ID: 24053653
[TBL] [Abstract][Full Text] [Related]
10. The novel dual-mechanism Kv7 potassium channel/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model.
Bloms-Funke P; Bankstahl M; Bankstahl J; Kneip C; Schröder W; Löscher W
Neuropharmacology; 2022 Feb; 203():108884. PubMed ID: 34785163
[TBL] [Abstract][Full Text] [Related]
11. ACS chemical neuroscience molecule spotlight on Potiga (Ezogabine).
Hopkins CR
ACS Chem Neurosci; 2012 Aug; 3(8):632. PubMed ID: 22896808
[TBL] [Abstract][Full Text] [Related]
12. New antiepileptic drugs: focus on ezogabine, clobazam, and perampanel.
Rudzinski LA; Vélez-Ruiz NJ; Gedzelman ER; Mauricio EA; Shih JJ; Karakis I
J Investig Med; 2016 Aug; 64(6):1087-101. PubMed ID: 27252470
[TBL] [Abstract][Full Text] [Related]
13. Ezogabine (Potiga) for epilepsy.
Med Lett Drugs Ther; 2012 Aug; 54(1397):65-7. PubMed ID: 22907178
[No Abstract] [Full Text] [Related]
14. Ezogabine (retigabine).
Stafstrom CE; Grippon S; Kirkpatrick P
Nat Rev Drug Discov; 2011 Sep; 10(10):729-30. PubMed ID: 21959281
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy.
Brodie MJ; Lerche H; Gil-Nagel A; Elger C; Hall S; Shin P; Nohria V; Mansbach H;
Neurology; 2010 Nov; 75(20):1817-24. PubMed ID: 20944074
[TBL] [Abstract][Full Text] [Related]
16. Impact of the KCNQ2/3 Channel Opener Ezogabine on Reward Circuit Activity and Clinical Symptoms in Depression: Results From a Randomized Controlled Trial.
Costi S; Morris LS; Kirkwood KA; Hoch M; Corniquel M; Vo-Le B; Iqbal T; Chadha N; Pizzagalli DA; Whitton A; Bevilacqua L; Jha MK; Ursu S; Swann AC; Collins KA; Salas R; Bagiella E; Parides MK; Stern ER; Iosifescu DV; Han MH; Mathew SJ; Murrough JW
Am J Psychiatry; 2021 May; 178(5):437-446. PubMed ID: 33653118
[TBL] [Abstract][Full Text] [Related]
17. Adjunctive use of ezogabine/retigabine with either traditional sodium channel blocking antiepileptic drugs (AEDs) or AEDs with other mechanisms of action: Evaluation of efficacy and tolerability.
Brodie MJ; French JA; McDonald SA; Lee WJ; Adams B; Scott A; Nohria V; DeRossett S
Epilepsy Res; 2014 Jul; 108(5):989-94. PubMed ID: 24726452
[TBL] [Abstract][Full Text] [Related]
18. The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use.
Large CH; Sokal DM; Nehlig A; Gunthorpe MJ; Sankar R; Crean CS; Vanlandingham KE; White HS
Epilepsia; 2012 Mar; 53(3):425-36. PubMed ID: 22221318
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for potassium channel openers in neuronal ion channel disorders?
Lawson K
Expert Opin Investig Drugs; 2000 Oct; 9(10):2269-80. PubMed ID: 11060806
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive retigabine in refractory focal epilepsy: Postmarketing experience at four tertiary epilepsy care centers in Germany.
Nass RD; Kurth C; Kull A; Graf W; Kasper B; Hamer HM; Strzelczyk A; Elger CE; Steinhoff BJ; Surges R; Rosenow F
Epilepsy Behav; 2016 Mar; 56():54-8. PubMed ID: 26828693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
